Unicycive Therapeutics received orphan drug designation for UNI-494 and its treatment was reviewed by the FDA.
5 reports, 1 independent
Updated Aug 12
Gone quiet
- Reports
- 5
- Developments
- 1
- Repetition
- 80%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Unicycive Therapeutics received orphan drug designation for UNI-494 and its treatment was reviewed by the FDA.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
-
Unicycive Therapeutics, Inc.
Unicycive Theraputics (Nasdaq: UNCY) is a clinical-stage biotechnology company focused on developing kidney medications
Nothing else this week.
- FDA
Related events
Coverage
Newest first; wire copies grouped- GlobeNewswireUnicycive Therapeutics to Participate in Upcoming Investor Events in September LOS ALTOS, Calif., Aug. 26, 2025 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical-stage biote
- GlobeNewswireUnicycive Therapeutics Announces Second Quarter 2025 Financial Results and Provides Business Update - Type A Meeting requested with U.S. Food and Drug Administration (FDA) for resolution of the Compl
- Unknown outlet